Engineering a thermostable human prolyl endopeptidase for antibody-directed enzyme prodrug therapy

Biochemistry

Volumn 43, Issue 20, 2004, Pages 6293-6303

  Heinis, Christian ^a   Alessi, Patrizia ^a   Neri, Dario ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; ASSAYS; BACTERIOPHAGES; BODY FLUIDS; DRUG THERAPY; ESCHERICHIA COLI; MUTAGENESIS;

ENDOPEPTIDASE; VIRAL INFECTIVITY;

ENZYMES;

(BENZYLOXYCARBONYL)GLYCYLPROLYLDOXORUBICIN; (BENZYLOXYCARBONYL)GLYCYLPROLYLMELPHALAN; ANTIBODY CONJUGATE; BUFFER; DIPEPTIDE; DOXORUBICIN; FIBRONECTIN; GLUTAMIC ACID; GLYCINE; MELPHALAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY L19; MUTANT PROTEIN; PEPTIDE DERIVATIVE; PRODRUG; PROLINE; PROLYL ENDOPEPTIDASE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CELL KILLING; CHEMICAL INTERACTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; COVALENT BOND; DRUG ACTIVATION; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME ASSAY; ENZYME ENGINEERING; ENZYME INACTIVATION; ENZYME PURIFICATION; ENZYME STABILITY; ENZYME STRUCTURE; ESCHERICHIA COLI; GENE MUTATION; HUMAN; HUMAN CELL; MOLECULAR CLONING; MYELOMA CELL; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; STEREOSPECIFICITY; TECHNIQUE; TEMPERATURE DEPENDENCE; TERATOCARCINOMA; THERMOSTABILITY; TUMOR LOCALIZATION; VIRUS INFECTIVITY;

ANIMALS; ANTIBODIES; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL LINE, TUMOR; DIRECTED MOLECULAR EVOLUTION; DRUG DESIGN; ENZYME STABILITY; HUMANS; IMMUNOCONJUGATES; MELPHALAN; MICE; MOLECULAR STRUCTURE; PEPTIDES; PRODRUGS; PROLINE; PROTEIN ENGINEERING; SERINE ENDOPEPTIDASES; TOXICITY TESTS;

ANIMALIA; ESCHERICHIA COLI; UNIDENTIFIED BACTERIOPHAGE;

EID: 2442710337     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi0361160     Document Type: Article

References (62)

1. Pratt, W. B., Ruddon, R. W., Ensminger, W. D., and Maybaum, J. (1994) The Anticancer Drugs, 2nd ed., Oxford University Press, New York.
2. Carter, P. (2001) Improving the efficacy of antibody-based cancer therapies, Nat. Rev. Cancer 1, 118-129.
3. Presta, L. G. (2002) Engineering antibodies for therapy, Curr. Pharm. Biotechnol. 3, 237-256.
4. Bagshawe, K. D., Sharma, S. K., Burke, P. J., Melton, R. G., and Knox, R. J. (1999) Developments with targeted enzymes in cancer therapy, Curr. Opin. Immunol. 11, 579-583.
5. Senter, P. D., and Springer, C. J. (2001) Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates, Adv. Drug Deliv. Rev. 53, 247-264.
6. Senter, P. D., Saulnier, M. G., Schreiber, G. J., Hirschberg, D. L., Brown, J. P., Hellstrom, I., and Hellstrom, K. E. (1988) Antitumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate, Proc. Natl. Acad. Sci. U.S.A. 85, 4842-4846.
7. Senter, P. D., Schreiber, G. J., Hirschberg, D. L., Ashe, S. A., Hellstrom, K. E., and Hellstrom, I. (1989) Enhancement of the in vitro and in vivo antitumor activities of phosphorylated mitomycin C and etoposide derivatives by monoclonal antibody-alkaline phosphatase conjugates, Cancer Res. 49, 5789-5792.
8. Wallace, P. M., and Senter, P. D. (1991) In vitro and in vivo activities of monoclonal antibody-alkaline phosphatase conjugates in combination with phenol mustard phosphate, Bioconjugate Chem. 2, 349-352.
9. Napier, M. P., Sharma, S. K., Springer, C. J., Bagshawe, K. D., Green, A. J., Martin, J., Stribbling, S. M., Cushen, N., O'Malley, D., and Begent, R. H. (2000) Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma, Clin. Cancer Res. 6, 765-772.
10. Martin, J., Stribbling, S. M., Poon, G. K., Begent, R. H., Napier, M., Sharma, S. K., and Springer, C. J. (1997) Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial, Cancer Chemother. Pharmacol. 40, 189-201.
11. Bagshawe, K. D., Springer, C. J., Searle, F., Antoniw, P., Sharma, S. K., Melton, R. G., and Sherwood, R. F. (1988) A cytotoxic agent can be generated selectively at cancer sites, Br. J. Cancer 58, 700-703.
12. Eccles, S. A., Court, W. J., Box, G. A., Dean, C. J., Melton, R. G., and Springer, C. J. (1994) Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185, Cancer Res. 54, 5171-5177.
13. Blakey, D. C., Burke, P. J., Davies, D. H., Dowell, R. I., East, S. J., Eckersley, K. P., Fitton, J. E., McDaid, J., Melton, R. G., Niculescu-Duvaz, I. A., Pinder, P. E., Sharma, S. K., Wright, A. F., and Springer, C. J. (1996) ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts, Cancer Res. 56, 3287-3292.
14. Kuefner, U., Lohrmann, U., Montejano, Y. D., Vitols, K. S., and Huennekens, F. M. (1989) Carboxypeptidase-mediated release of methotrexate from methotrexate alpha-peptides, Biochemistry 28, 2288-2297.
15. Haenseler, E., Esswein, A., Vitols, K. S., Montejano, Y., Mueller, B. M., Reisfeld, R. A., and Huennekens, F. M. (1992) Activation of methotrexate-alpha-alanine by carboxypeptidase A-monoclonal antibody conjugate, Biochemistry 31, 891-897.
16. Wolfe, L. A., Mullin, R. J., Laethem, R., Blumenkopf, T. A., Cory, M., Miller, J. F., Keith, B. R., Humphreys, J., and Smith, G. K. (1999) Antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1: in vitro and in vivo studies with prodrugs of methotrexate and the thymidylate synthase inhibitors GW1031 and GW1843, Bioconjugate Chem. 10, 38-48.
17. Smith, G. K., Banks, S., Blumenkopf, T. A., Cory, M., Humphreys, J., Laethem, R. M., Miller, J., Moxham, C. P., Mullin, R., Ray, P. H., Walton, L. M., and Wolfe, L. A., III (1997) Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate, J. Biol. Chem. 272, 15804-15816.
18. Kerr, D. E., Garrigues, U. S., Wallace, P. M., Hellstrom, K. E., Hellstrom, I., and Senter, P. D. (1993) Application of monoclonal antibodies against cytosine deaminase for the in vivo clearance of a cytosine deaminase immunoconjugate, Bioconjugate Chem. 4, 353-357.
19. Wallace, P. M., MacMaster, J. F., Smith, V. F., Kerr, D. E., Senter, P. D., and Cosand, W. L. (1994) Intratumoral generation of 5-fluorouracil mediated by an antibody-cytosine deaminase conjugate in combination with 5-fluorocytosine, Cancer Res. 54, 2719-2723.
20. Wang, S. M., Chern, J. W., Yeh, M. Y., Ng, J. C., Tung, E., and Roffler, S. R. (1992) Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy, Cancer Res. 52, 4484-4491.
21. Roffler, S. R., Wang, S. M., Chern, J. W., Yeh, M. Y., and Tung, E. (1991) Anti-neoplastic glucuronide prodrug treatment of human tumor cells targeted with a monoclonal antibody-enzyme conjugate, Biochem. Pharmacol. 42, 2062-2065.
22. Bosslet, K., Czech, J., and Hoffmann, D. (1994) Tumor-selective prodrug activation by fusion protein-mediated catalysis, Cancer Res. 54, 2151-2159.
23. Meyer, D. L., Jungheim, L. N., Law, K. L., Mikolajczyk, S. D., Shepherd, T. A., Mackensen, D. G., Briggs, S. L., and Starling, J. J. (1993) Site-specific prodrug activation by antibody-beta-lactamase conjugates: regression and long-term growth inhibition of human colon carcinoma xenograft models, Cancer Res. 53, 3956-3963.
24. Kerr, D. E., Schreiber, G. J., Vrudhula, V. M., Svensson, H. P., Hellstrom, I., Hellstrom, K. E., and Senter, P. D. (1995) Regressions and cures of melanoma xenografts following treatment with monoclonal antibody beta-lactamase conjugates in combination with anticancer prodrugs, Cancer Res. 55, 3558-3563.
25. Svensson, H. P., Vrudhula, V. M., Emswiler, J. E., MacMaster, J. F., Cosand, W. L., Senter, P. D., and Wallace, P. M. (1995) In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody beta-lactamase conjugates, Cancer Res. 55, 2357-2365.
26. Mauger, A. B., Burke, P. J., Somani, H. H., Friedlos, F., and Knox, R. J. (1994) Self-immolative prodrugs: candidates for antibody-directed enzyme prodrug therapy in conjunction with a nitrore-ductase enzyme, J. Med. Chem. 37, 3452-3458.
27. Friedlos, F., Denny, W. A., Palmer, B. D., and Springer, C. J. (1997) Mustard prodrugs for activation by Escherichia coli nitroreductase in gene-directed enzyme prodrug therapy, J. Med. Chem. 40, 1270-1275.
28. Bagshawe, K. D. (1989) The First Bagshawe lecture. Towards generating cytotoxic agents at cancer sites, Br. J. Cancer 60, 275-281.
29. Vrudhula, V. M., Senter, P. D., Fischer, K. J., and Wallace, P. M. (1993) Prodrugs of doxorubicin and melphalan and their activation by a monoclonal antibody-penicillin-G amidase conjugate, J. Med. Chem. 36, 919-923.
30. Bignami, G. S., Senter, P. D., Grothaus, P. G., Fischer, K. J., Humphreys, T., and Wallace, P. M. (1992) N-(4′ -hydroxyphenylacetyl)palytoxin: a palytoxin prodrug that can be activated by a monoclonal antibody-penicillin G amidase conjugate, Cancer Res. 52, 5759-5764.
31. Bhatia, J., Sharma, S. K., Chester, K. A., Pedley, R. B., Boden, R. W., Read, D. A., Boxer, G. M., Michael, N. P., and Begent, R. H. (2000) Catalytic activity of an in vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion protein, Int. J. Cancer 85, 571-577.
32. Francis, R. J., Sharma, S. K., Springer, C., Green, A. J., Hope-Stone, L. D., Sena, L., Martin, J., Adamson, K. L., Robbins, A., Gumbrell, L., O'Malley, D., Tsiompanou, E., Shahbakhti, H., Webley, S., Hochhauser, D., Hilson, A. J., Blakey, D., and Begent, R. H. (2002) A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours, Br. J. Cancer 87, 600-607.
33. Polgar, L. (1992) Unusual secondary specificity of prolyl oligopeptidase and the different reactivities of its two forms toward charged substrates, Biochemistry 31, 7729-7735.
34. Nomura, K. (1986) Specificity of prolyl endopeptidase, FEBS Lett. 209, 235-237.
35. Maes, M., Lin, A. H., Bonaccorso, S., Goossens, F., Van Gastel, A., Pioli, R., Delmeire, L., and Scharpe, S. (1999) Higher serum prolyl endopeptidase activity in patients with post-traumatic stress disorder, J. Affective Disord. 53, 27-34.
36. Fulop, V., Bocskei, Z., and Polgar, L. (1998) Prolyl oligopeptidase: an unusual beta-propeller domain regulates proteolysis, Cell 94, 161-170.
37. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning. A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
38. Fattorusso, R., Pellecchia, M., Viti, F., Neri, P., Neri, D., and Wuthrich, K. (1999) NMR structure of the human oncofoetal fibronectin ED-B domain, a specific marker for angiogenesis, Struct. Folding Des. 7, 381-390.
39. Heinis, C., Huber, A., Demartis, S., Bertschinger, J., Melkko, S., Lozzi, L., Neri, P., and Neri, D. (2001) Selection of catalytically active biotin ligase and trypsin mutants by phage display, Protein Eng. 14, 1043-1052.
40. Clackson, T., Hoogenboom, H. R., Griffiths, A. D., and Winter, G. (1991) Making antibody fragments using phage display libraries, Nature 352, 624-628.
41. Nissim, A., Hoogenboom, H. R., Tomlinson, I. M., Flynn, G., Midgley, C., Lane, D., and Winter, G. (1994) Antibody fragments from a 'single pot' phage display library as immunochemical reagents, EMBO J. 13, 692-698.
42. Leung, D. W., Chen, E., and Goeddel, D. V. (1989) A method for random mutagenesis of a defined DNA segment using a modified polymerase chain reaction, Technique 1, 11-15.
43. Borsi, L., Balza, E., Bestagno, M., Castellani, P., Carnemolla, B., Biro, A., Leprini, A., Sepulveda, J., Burrone, O., Neri, D. and Zardi, L. (2002) Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin, Int. J. Cancer 102, 75-85.
44. Halin, C., Rondini, S., Nilsson, F., Berndt, A., Kosmehl, H., Zardi, L., and Neri, D. (2002) Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature, Nat. Biotechnol. 20, 264-269.
45. Sommer, J. (1993) Synthesis of mammalian prolylendopeptidase in Escherichia coli and analysis of the recombinant protein, Biochim. Biophys. Acta 1173, 289-293.
46. Kristensen, P., and Winter, G. (1998) Proteolytic selection for protein folding using filamentous bacteriophages, Folding Des. 3, 321-328.
47. Sieber, V., Pluckthun, A., and Schmid, F. X. (1998) Selecting proteins with improved stability by a phage-based method, Nat. Biotechnol. 16, 955-960.
48. Borsi, L., Balza, E., Carnemolla, B., Sassi, F., Castellani, P., Berndt, A., Kosmehl, H., Biro, A., Siri, A., Orecchia, P., Grassi, J., Neri, D., and Zardi, L. (2003) Selective targeted delivery of TNF{alpha} to tumor blood vessels, Blood 102, 4384-4392.
49. Santimaria, M., Moscatelli, G., Viale, G. L., Giovannoni, L., Neri, G., Viti, F., Leprini, A., Borsi, L., Castellani, P., Zardi, L., Neri, D., and Riva, P. (2003) Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer, Clin. Cancer Res. 9, 571-579.
50. Tarli, L., Balza, E., Viti, F., Borsi, L., Castellani, P., Berndorff, D., Dinkelborg, L., Neri, D., and Zardi, L. (1999) A high-affinity human antibody that targets tumoral blood vessels, Blood 94, 192-198.
51. Viti, F., Tarli, L., Giovannoni, L., Zardi, L., and Neri, D. (1999) Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis, Cancer Res. 59, 347-352.
52. Chatellier, J., Hartley, O., Griffiths, A. D., Fersht, A. R., Winter, G., and Riechmann, L. (1999) Interdomain interactions within the gene 3 protein of filamentous phage, FEBS Lett. 463, 371-374.
53. Altmann, K. H. (2003) Epothilone B and its analogues-a new family of anticancer agents, Mini-Rev. Med. Chem. 3, 149-158.
54. Sasse, F., Steinmetz, H., Heil, J., Hofle, G., and Reichenbach, H. (2000) Tubulysins, new cytostatic peptides from myxobacteria acting on microtubuli. Production, isolation, physicochemical and biological properties, J. Antibiot. (Tokyo) 53, 879-885.
55. Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F., DeBlanc, R. L., Gearing, R. P., Bovee, T. D., Siegall, C. B., Francisco, J. A., Wahl, A. F., Meyer, D. L., and Senter, P. D. (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy, Nat. Biotechnol. 21, 778-784.
56. Pini, A., Viti, F., Santucci, A., Carnemolla, B., Zardi, L., Neri, P., and Neri, D. (1998) Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel, J. Biol. Chem. 273, 21769-21776.
57. Castellani, P., Viale, G., Dorcaratto, A., Nicolo, G., Kaczmarek, J., Querze, G., and Zardi, L. (1994) The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis, Int. J. Cancer 59, 612-618.
58. Castellani, P., Borsi, L., Camemolla, B., Biro, A., Dorcaratto, A., Viale, G. L., Neri, D., and Zardi, L. (2002) Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin, Am. J. Pathol. 161, 1695-1700.
59. Birchler, M., Viti, F., Zardi, L., Spiess, B., and Neri, D. (1999) Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment, Nat. Biotechnol. 17, 984-988.
60. Nilsson, F., Kosmehl, H., Zardi, L., and Neri, D. (2001) Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice, Cancer Res. 61, 711-716.
61. Carnemolla, B., Borsi, L., Balza, E., Castellani, P., Meazza, R., Berndt, A., Ferrini, S., Kosmehl, H., Neri, D., and Zardi, L. (2002) Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix, Blood 99, 1659-1665.
62. Halin, C., Gafner, V., Villani, M. E., Borsi, L., Berndt, A., Kosmehl, H., Zardi, L., and Neri, D. (2003) Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha, Cancer Res. 63, 3202-3210.